SMARTProbe -: An informative biopsy needle with bioimpedance sensing for real-time breast lesion screening by Ugwah, Justina A. et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title SMARTProbe -: An informative biopsy needle with bioimpedance
sensing for real-time breast lesion screening
Author(s) Ugwah, Justina A.; Bennett, Bill; O'Donnell, Brian; O'Sullivan, Martin;
Moore, Eric
Publication date 2019-04
Original citation Ugwah, J. A., Bennett, B., O'Donnell, B., O'Sullivan, M. and Moore, E.
(2019) 'SMARTProbe -: An informative biopsy needle with
bioimpedance sensing for real-time breast lesion screening', Smart
Systems Integration; 13th International Conference and Exhibition on
Integration Issues of Miniaturized Systems, Barcelona, Spain, 10-11
April, pp. 344-347. Available at:
https://ieeexplore.ieee.org/abstract/document/8727824 (Accessed: 17
August 2021)





Access to the full text of the published version may require a
subscription.





Smart Systems Integration · Barcelona, Spain, 10 – 11 April 2019
SMARTProbe -: An informative biopsy needle with bioimpedance sensing 
for real-time breast lesion screening 
Justina A. Ugwah a, Bill Bennett b, Brian O’Donnell c,d, Martin O’Sullivan d , Eric Moore *a 
a Life Science Interface, Sensing & Separation Group, Tyndall National Institute, School 
of Chemistry, University College, Cork 
b Department of Histopathology, Cork University Hospital, Cork 
c Cork Academy of Regional Anaesthesia  
d BreastCheck & Cork University Hospital, Cork 
*Corresponding author email: e.moore@ucc.ie
Abstract 
Patients who present with a breast lesion require clinical and radiological examination 
for breast disease detection. For a definitive diagnosis, biopsy under ultrasound 
guidance is performed for histological assessment to determine if lesion is malignant or 
benign. The biopsy needle, currently a passive instrument, if integrated with impedance 
sensing, can give real time information for use as a tissue discriminating tool.  
Bio-impedance is a technique which enables the use of three variables (resistance, 
reactance and phase angle) as indices of structural and functional biological variables. 
The frequency dependent electrical impulse gives the physiology and pathological 
information about the conductive and dielectric properties of cells. The differences in 
electrical properties of malignant and healthy tissues are associated with increased 
water and mineral content within tumor cells, the changes in membrane permeability, 
altered packing density as well as orientation of cells.  
The prototype SMARTProbe, with bioimpedance sensing, is able to discriminate healthy 
tissue from malignant and benign lesions in ex-vivo clinical investigation. The fabrication 
process of sensors allows for defined and constant electrode distance, which enables 
small alternate current to be used, thus, decreasing variability as a result of tissue 
heterogeneity. 
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Introduction
According to the 2014 National Cancer Registry Ireland, 19,000 people are diagnosed 
with cancer every year, with over 8000 deaths reported yearly. It is estimated that 
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breast cancer constitutes 22% of all female invasive cancer[1]. In Ireland, the annual 
average incidence for invasive breast cancer was 2,805 cases per annum between 
2009 and 2011, which represents 31% of female invasive cancers (excluding non-
melanoma skin cancer). The number of cases of female breast cancer is expected to 
increase by about 130% between 2010 and 2040 [2]. Cancer diagnosis, staging and 
treatment is a major health care challenge, which involves assessment by a 
multidisciplinary team that includes, breast consultants, radiology and histopathology 
experts One of the objectives for the rational for a national clinical guideline by the 
cancer control in Ireland include: improvements in the quality of clinical decisions. There 
is a need for a diagnostic adjunct technology which can give clinicians, real time 
information on a lesion presented at the breast clinic, this is the niche the SMARTProbe 
hopes to address. 
The SMARTProbe is an informative biopsy needle with bioimpedance sensing for 
tissue-type differentiation. Bioimpedance, as a sensing technique, can provide rapid 
information regarding the cellular and architectural composition of tissue as a result of 
its electric properties. It’s of interest to note that the highly insulating cell membranes 
limits electric current in living tissue, but the different tissue architecture such as cancer 
may impede current differently, to allow for normal and malignant tissue differentiation.  
Materials and Method 
Ethical approval was taken from the CREC, for the clinical investigation to be carried out 
at the Cork University hospital. Protocols that meet clinical standards were developed 
during the clinical investigation of the ex-vivo breast tissue and lesions.  
The SMARTProbe was inserted into the tissue by direct puncture and this was held in 
place by the tissue and no bleeding noticed. A sinusoidal current is driven to the tissue 
to generate a voltage response for the bioimpedance measurements. . To do this the 
two electrode probe is connected to the potentiostat (PGSTAT204, Metrohm Autolab 
B.V., Netherlands) as seen in figure 1. The bioimpedance of healthy tissue is measured 
first with the SMARTProbe because of the heterogeneity of each individuals breast 
tissue which may be as a result of hormonal changes, menopause, ageing. The 
bioimpedance of the breast lesion is then done to compare with that of the healthy 
tissue. If two lesions are identified during the radiological assessment, the two different 
lesions are also measured and compared to tissues from other patients with the same 
histologically diagnosed cancer subtype. The data is then exported to excel and SPSS 
where it is analysed. 
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Fig 1a SMARTProbe in an excised breast lesion     
Test FRA calibration of instrument is done on the dummy cell before each clinical 
investigation to ensure the equipment is calibrated and values are not out of range. The 
measurement in different concentration of saline (0.45%, 0.9% and 1.8%) is done at a 
fixed frequency, 10 kHz, to ensure sensors are working well. Three measurements are 
taken in the healthy tissue and also in the breast lesion and average of each tissue type 
used. The measurements taken are done within an hour of it being excised and then put 
into formalin to undergo the full processes required for pathological assessments.  
Temperature measurements are also taken during the measurements. A frequency 
band of 100Hz to 1MHz is used at an amplitude of 100nA to 1mA in 50 equal interval 
points. A frequency sweep is used as opposed to a fixed frequency as 50 impedance 
and phase angle measurements contains more information as a spectrum. 
Discussion 
The small distance between the current injecting and pick-up electrode was small 
enough that the impedance measurement is localized and only the dielectric properties 
of the tissue surrounding the needle tip was is obtained; thus, position error is avoided. 
In our study, the impedance magnitude of Invasive ductal carcinoma, IDC is higher than 
the healthy tissue while the Invasive lobular carcinoma, ILC, it is lower. The 
SMARTProbe could significantly differentiate between healthy and cancerous tissue at 
frequencies between 100 Hz - 60 kHz. 
Patient 25 has two malignant tumour subtype, IDC and ILC and has also had neo-
adjuvant chemotherapy before excisional biopsy.
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Fig 2 Impedance magnitude of patients 25 
Conclusion
The SMARTProbe can discriminate between healthy and cancerous tissue and has 
shown sensitivity for differentiating between the Invasive ductal carcinoma and lobular 
carcinoma. It is presumed that similar results will be obtained in vivo, as measurements 
were carried out shortly after excision, before the onset of loss of tissue viability and 
function that can affect its dielectric properties. More data is required to be able to 
ensure sensitivity and specificity. Also more patients who have received neo-adjuvant 
chemotherapy will need to be investigated. No male patient was consented in this study 
to date and the bioimpedance of male breast tissue will be of interest. 
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